University of California San Francisco
Give to UCSF<p>The AIDS drug Truvada, approved this week for prevention of HIV infection in uninfected people at high risk, may benefit many uninfected women whose male partners have HIV, including pregnant women, who may be at higher risk.</p>
<p>The year 1982 was pivotal for Paul Volberding, MD. In the early days of the AIDS crisis, he was a talented research fellow who was getting ready to help launch San Francisco General Hospital & Trauma Center’s Ward 86, which would become the world’s first HIV/AIDS outpatient clinic. It opened its doors the following year.</p>
<p>On the eve of the XIX International AIDS Conference in Washington, D.C., UCSF's Jay Levy paused recently to reflect on HIV — a disease that has defined a generation, continues to plague the world and may yet be vanquished.</p>
<p>The first U.S. meeting of the International AIDS Conference in more than two decades will be held later this month in Washington, DC, and Bay Area reporters got a preview of what UCSF researchers will present when they convene at the nation's capitol.</p>
<p>A declaration calling for global support to end the AIDS epidemic was announced on July 10 by the International AIDS Society, with key support from the University of California, San Francisco (UCSF).</p>
<p>UCSF teams are working hard to achieve a collective fundraising goal of $55,000 in AIDS Walk San Francisco, which is on July 15.</p>
An investigation led by UCSF has found that the risk of female-to-male HIV transmission is increased three fold for women with bacterial vaginosis, a common disorder in which the normal balance of bacteria in the vagina is disrupted.
After being infected with simian immunodeficiency virus (SIV) in a laboratory study, rhesus macaques that had more of a certain type of immune cell in their gut than others had much lower levels of the virus in their blood, and for six months after infection were better able to control the virus.